Research from University of Chicago shows that lipid nanoparticles can effectively deliver mRNA to beta cells. mRNA coding for cell-surface antigen PD-L1 enhances the cells’ immune protection, thus preserving insulin production.
This is early-stage research. We don’t know when it might turn into a therapy, get into human trials, and be approved for clinical use.
Research on preventing type 1 diabetes often focuses on limiting the autoimmune response that destroys the body’s ability to produce its own insulin. A new technology developed by scientists at the University of Chicago takes a different approach, centered on preserving insulin-producing beta cells by giving them the ability to protect themselves.
In a new study published this week in Cell Reports Medicine, researchers showed how nanoparticles created with lipids can deliver mRNA molecules to beta cells and prompt them to express more PD-L1, a cell surface protein that helps evade the immune system. In experiments with both mouse and human beta cells, the nanoparticles successfully reached their target and triggered PD-L1 expression. The same approach also worked in a model where human beta cells were transplanted into mice.
by JR Enriquez · 2026 — In prediabetic NOD mice, LNP delivery of PD-L1 mRNA induces β cell PD-L1 expression, attenuates insulitis, and delays the onset of autoimmune ...
by R van Tienhoven · 2025 · Cited by 14 — A protective INS SNP causes accelerated IRE1α-dependent decay of insulin mRNA. This protective mechanism alleviates ER stress and reduces beta-cell ...
Delivering mRNA Therapeutics to the Pancreas - News
Feb 3, 2023 — The vision is to use mRNA to reprogram pancreatic alpha cells to produce insulin. Delivering mRNA to the pancreas could subsequently provide ...
by Y Xue · 2024 · Cited by 77 — Delivery of saRNA and E3 mRNA complex (SEC) using DIM1T LNPs facilitates prolonged protein production in ASCs. Sustained protein production by ...
